Printed from Voxsanity (voxsanity.com.au) — NCT06790394 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
Back to Peripheral Neuropathy
Phase 1 Peripheral Neuropathy Trial, Recruiting
NCT06790394
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 40 years or older, of any gender
- People who are able to understand and sign a consent form before any study activities begin
- Women who are either surgically unable to become pregnant (through removal of the uterus, fallopian tubes, or ovaries) or who have been through menopause for at least one year, OR women who could become pregnant but are willing to use a reliable form of contraception for at least one week after the PET scan
- Men who are willing to use a reliable form of contraception with their partner for at least 90 days after the PET scan, and who agree not to donate sperm for at least 90 days after the scan
- People whose medications for multiple myeloma, chronic heart conditions, or a treatment called tafamidis have been at a stable dose
- People on stable blood-thinning medication, if a blood sample from an artery is required
- People who have been diagnosed with a type of heart amyloidosis (either AL or ATTR type) according to recognised medical diagnostic standards
- Control group participants, meaning people without heart failure and no suspicion of heart amyloidosis, OR people with reduced heart function where heart amyloidosis has been ruled out by specific tests, OR people with a blood cell condition called MGUS or multiple myeloma but where no signs of heart amyloidosis have been found on heart scans
Who may not be able to join:
- People who have received or are currently receiving a type of antibody treatment that targets amyloid, within the past 3 months
- People with a known allergy or sensitivity to any ingredient in the study drug
- People whose blood haemoglobin level is below 10 g/dL (confirm with trial site)
- People with severe liver problems, based on specific liver test results being significantly above normal levels (confirm with trial site)
- People currently receiving kidney dialysis (haemodialysis or peritoneal dialysis)
- People who are unable to lie flat for up to 60 minutes
- People who are pregnant, breastfeeding, or currently lactating
- People who are unwilling or unable to follow the study procedures
- People who have had a PET scan within one week before the study's PET scan
- People who need an arterial blood sample taken but have a medical reason why a needle cannot safely be placed in an artery — for example, allergy to local anaesthetic, poor circulation in the limbs, a condition called Raynaud's phenomenon, or abnormal blood clotting results at the screening stage
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.
Contact this trial
Phone: 004930461124660
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Status
Recruiting
Phase
Phase 1
Sponsor
Lantheus Germany GmbH
Registry
ClinicalTrials.gov
Start date
21 October 2025
Est. completion
1 September 2026
Where this trial is recruiting
🇬🇧 United Kingdom
Primary endpoints
Test-Retest variability of cardiac [18F]florbetaben PET uptake
Can't join this trial?
Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.